Dennis Awuah

Dr. Dennis Awuah

City of Hope
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
FSFabián Salazar
Fabián Salazar
LHLaurence Hall
Laurence Hall
ONOla H. Negm
Ola H. Negm
DADennis Awuah
Dennis Awuah
Patrick TighePatrick Tighe
Patrick Tighe
AGAmir M Ghaemmaghami
Amir M Ghaemmaghami

18 January 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
XWXiuli Wang
Xiuli Wang
ZDZhenyuan Dong
Zhenyuan Dong
DADennis Awuah
Dennis Awuah
WCWen-Chung Chang
Wen-Chung Chang
WCWesley Cheng
Wesley Cheng
HQHong Qin
Hong Qin

15 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
VAVikram Adhikarla
Vikram Adhikarla
DADennis Awuah
Dennis Awuah
ABAlexander Brummer
Alexander Brummer
ECEnrico Caserta
Enrico Caserta
AKAmrita Krishnan
Amrita Krishnan
RRRussell Rockne
Russell Rockne
Targeted radionuclide therapy (TRT) has recently seen a surge in popularity with the use of radionuclides conjugated to small molecules and antibodies. Similarly, immunotherapy also has shown promising results, an example being chimeric antigen receptor T cell (CAR-T) therapy in hematologic malignancies. Moreover, TRT and CAR-T therapies possess unique features that require special consideration when determining how to dose as well as the timing and sequence of combination treatments including the distribution of the TRT dose in the body, the decay rate of the radionuclide, and the proliferation and persistence of the CAR-T cells. These characteristics complicate the additive or synergistic effects of combination therapies and warrant a mathematical treatment that includes these dynamics in relation to the proliferation and clearance rates of the target tumor cells. Here, we combine two previously published mathematical models to explore the effects of dose, timing, and sequencing of TRT and CAR-T cell-based therapies in a multiple myeloma setting. We find that, for a fixed TRT and CAR-T cell dose, the tumor proliferation rate is the most important parameter in determining the best timing of TRT and CAR-T therapies.

6 November 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
DADennis Awuah
Dennis Awuah
ARAlisa Ruisinger
Alisa Ruisinger
Meshal A AlobaidMeshal A Alobaid
Meshal A Alobaid
CMChidimma Mbadugha
Chidimma Mbadugha
AGAmir M Ghaemmaghami
Amir M Ghaemmaghami
The peroxisome proliferator activated receptor gamma (PPARγ) is a ligand activated transcription factor expressed in dendritic cells (DCs), where it exerts anti-inflammatory responses against TLR4-induced inflammation. Recently, microRNA-511 (miR-511) has also emerged as a key player in controlling TLR4-mediated signalling, and in regulating the function of DCs. Interestingly, PPARγ has been previously highlighted as a putative target of miR-511 activity; however the link between miR-511 and PPARγ and its influence on human DC function within the context of LPS-induced inflammatory responses is unknown. Using a selection of miR-511-3p-specific inhibitors and mimics, we demonstrate for the first time that up or downregulation of miR-511-3p inversely correlates with PPARγ mRNA levels and transcriptional activity following treatment with PPARγ synthetic agonist rosiglitazone (RSG), in the presence or absence of LPS. Additionally, we show that PPARγ activation with RSG modulates LPS-induced DC activation and downregulates pro-inflammatory cytokine production following downregulation of miR-511-3p. Lastly, PPARγ activation was shown to suppress LPS-mediated induction of indoleamine 2,3-dioxygenase (IDO) activity in DCs, most likely due to changes in miR-511-3p expression. These data suggest that PPARγ-induced modulation of DC phenotype and function is influenced by miR-511-3p expression, which may serve as a potential therapeutic target against inflammatory diseases.

17 September 2021 in Preprints.org
Verified
Preprint
Open access
VAVikram Adhikarla
Vikram Adhikarla
DADennis Awuah
Dennis Awuah
ABAlex Brummer
Alex Brummer
ECEnrico Caserta
Enrico Caserta
AKAmrita Krishnan
Amrita Krishnan
RRRussell Rockne
Russell Rockne
Targeted radionuclide therapy (TRT) has recently seen a surge in popularity, with the use of radionuclides conjugated to small molecules and antibodies. Similarly, immunotherapy also has shown promising results – an example being chimeric antigen receptor (CAR) T-cells therapy in hematologic malignancies. Moreover, TRT and CAR T therapies possess unique features that require special consideration when determining how to dose, time, and sequence combination treatments, including the distribution of TRT dose in the body, the decay rate of the radionuclide, and the proliferation and persistence of the CAR-T cells. These characteristics complicate additive or synergistic effects of combination therapies and warrant a mathematical treatment which includes these dynamics in relation to the proliferation and clearance rates of the target tumor cells. Here we combine two previously published mathematical models in a multiple myeloma setting to explore the effects of dose, timing, and sequencing of TRT and CAR-T cell based therapies. We find that for a fixed TRT and CAR-T cell dose, the tumor proliferation rate is the most important parameter in determining the best timing of TRT and CAR T therapies.

29 August 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAshlie Munoz
Ashlie Munoz
RURyan Urak
Ryan Urak
ETEllie Taus
Ellie Taus
CHClaire Hsieh
Claire Hsieh
KJKatherine S Jin
Katherine S Jin
XWXiuli Wang
Xiuli Wang
Dexamethasone (dex) is a glucocorticoid that is a mainstay for treatment of inflammatory pathologies, including immunotherapy-associated toxicities. Dex suppresses the endogenous immune response and is also believed to suppress the function of chimeric antigen receptor (CAR) T cells. However, recent reports observed higher CAR T cell numbers in patients treated with dex, highlighting the rationale for interrogating the specific effects of dex on CAR T cells. Here, we found that dex did not inhibit CAR T cell expansion or function. A single dose of dex during the manufacturing process upregulated the pro-persistence interleukin 7 receptor α (IL7Rα) on CAR T cells and induced expression of genes involved in activation, migration, and persistence. The ex vivo upregulation of IL7Rα induced by dex significantly enhanced CAR T cell persistence and anti-tumor efficacy in vivo when combined with exogenous IL-7. Moreover, the combination of dex and IL-7 resulted in increased persistence of CAR T cells and led to complete remission of mice. Overall, our studies in both in vitro and in vivo treatment support a positive role of dex on CAR T cell potency and provide insight into the application of glucocorticoids in cellular anti-cancer therapy.